CDK9-IN-33

• Description :

  CDK9-IN-33 (compound C35) is a potent, selective and orally active CDK9 inhibitor with IC50 values of 17.44, 160, 316.30, 1771.00, >10000 nM for CDK9, CDK7, CDK2, CDK4, CDK6 respectively. CDK9-IN-33 induces apoptosis. CDK9-IN-33 decreases the protein expression of RPB1 CTD Ser2, RPB1, MCL1. CDK9-IN-33 shows anti-tumor activity[1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; CDK

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Cell Cycle/DNA Damage

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/cdk9-in-33.html

• Smiles :

  CC(C1=C2N=C(N=C(N2N=C1)NCC3=CC=C(C=C3)NC(CC)=O)NC4CCOCC4)C

• Molecular Formula :

  C23H31N7O2

• Molecular Weight :

  437.54

• References & Citations :

  [1]Wang WJ, et al. Discovery of Orally Bioavailable and Potent CDK9 Inhibitors for Targeting Transcription Regulation in Triple-Negative Breast Cancer. J Med Chem. 2024 Jun 27;67 (12) :10035-10056.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  CDK2; CDK4; CDK6; CDK7; CDK9